NCT02536794: MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable progressing brain metastases or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT02536794

Comments are closed.

Up ↑